NASDAQ: GILD · General Drug Manufacturers
Gilead Sciences (GILD) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Gilead Sciences (GILD) at $219.16 a share. The stock last closed at $167.58, which puts the model's fair value 30.8% above the price. On the model's bands that reads as Undervalued.
Revalued . Price is the close of 16 Nov 2026. Gilead Sciences, Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $165.62 to $219.16 (+32.3%). The model's quality adjustment to the peer multiple moved, lifting the fair value: most of the move.
What the model makes of itThe price of $167.58 is 30.8% below it: Undervalued, on a medium evidence grade.
What's nextNext report on 9 Feb 2027. Options prices imply a move of about 9% either way over the next month. On the model's Earnings Momentum list since 22 Oct 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give GILD?
The calibrated range for GILD over 63 trading days is $150.67 to $187.39. It sits around the last close, and its width comes from the volatility that GILD's own options imply (32% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $186.38 to $253.86. In 92% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Gilead Sciences, Inc. (GILD) is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. It sits in Healthcare, within General Drug Manufacturers.
Faircurve's model put the fair value at $219.16 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $165.62, so the fair value moved +32.3%. In the model's words, the quality adjustment to the peer multiple moved, lifting the fair value: most of the move. The calibrated range over 63 trading days is $150.67 to $187.39. Ranges built this way held the price 60% of the time at this horizon, based on 8,038 past valuations refreshed 14 Nov 2026. The evidence grade is Medium. The grade weighs input completeness, the comparables and the spread of outcomes. It does not say whether the fair value is right.
Gilead scores 73 out of 100 on quality against comparable companies. Profitability scores 100, with ROIC of 35.7% against a peer median of 10.0%. Balance sheet scores 0, with net debt to EBITDA of 15.32x against a peer median of 0.63x. The model compares Gilead with Amgen, Pfizer, Bristol-Myers Squibb, Merck, AbbVie, Johnson & Johnson, Biogen and Eli Lilly.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does GILD report earnings, and how has the stock reacted?
Gilead Sciences's next earnings report is scheduled for 9 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 4.3% in either direction through the nearest expiry, about 10 days out. That is the size the market is pricing, not a direction. GILD's 30 day implied volatility works out to about 9.3% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across GILD's last 8 reports, ignoring direction, was 3.3%.
What the options market has priced for a month's move in GILD
How does GILD score on business quality?
Gilead Sciences's overall quality score is 73 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 100 | 35.7%ROIC | 10.0% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 100 | ||
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 60 | 2.4%Revenue growth, trailing | 1.4% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 72 | 0.7%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 0 | 15.32xNet debt / EBITDA | 0.63x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 35 | 8.7 ptsEBITDA margin downside volatility, 5y | 4.5 pts |
How does GILD compare with similar companies?
The companies in general drug manufacturers closest to Gilead Sciences in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| AMGN Amgen Inc. | $462.32 | $479.14 | +3.6% | Fairly valued |
| PFE Pfizer Inc. | $28.86 | $33.13 | +14.8% | Fairly valued |
| BMY Bristol-Myers Squibb Company | $62.93 | $68.95 | +9.6% | Fairly valued |
| MRK Merck & Co., Inc. | $144.46 | $126.11 | -12.7% | Fairly valued |
| ABBV AbbVie Inc. | $294.55 | $298.37 | +1.3% | Fairly valued |
| JNJ Johnson & Johnson | $282.55 | $226.25 | -19.9% | Overvalued |
| BIIB Biogen Inc. | $251.65 | $256.53 | +1.9% | Fairly valued |
| LLY Eli Lilly and Company | $1,431.67 | $1,125.83 | -21.4% | Overvalued |
What the comparable companies' multiples alone would give for GILD, the peer-implied price, is $289.81 a share on this run. The fair value weighs that against the company's own multiple.
All general drug manufacturer stocks ranked by gap to fair value
Gilead Sciences at a glance
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets.
- Market value
- $208.5B
- Sector
- Healthcare
- Industry
- General Drug Manufacturers
- Revenue expected, next twelve months
- $33.3B
- Consensus revenue growth, next fiscal year
- +6.4%
- Analysts with estimates
- 15
- Beta to the US market
- 0.24
- First valued by Faircurve
- 1 May 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. GILD was among them.
How the fair value is worked out: the model prices Gilead Sciences on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for GILD was $165.62. As of 14 Nov 2026 it is $219.16, a change of +32.3%. The model's quality adjustment to the peer multiple moved, lifting the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Gilead Sciences's valuation
Is Gilead Sciences stock undervalued or overvalued?
On Faircurve's model, GILD reads as Undervalued as of 14 Nov 2026. The model's fair value is $219.16 a share against a last close of $167.58, a gap of +30.8%.
What is GILD's fair value?
$219.16 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $186.38 to $253.86.
What price range does the model give GILD?
$150.67 to $187.39 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Gilead Sciences report earnings next?
The next report is scheduled for 9 Feb 2027. Companies can move their dates.
How much has GILD moved on past earnings reports?
Across its last 8 reports the median two session move was 3.3%, ignoring direction. The largest was +8.3% around the report of 7 Aug 2025.
How confident is the model in this valuation?
The model's evidence grade for GILD is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on GILD
The model has an idea open on GILD under Earnings Momentum since 22 Oct 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on GILD with their outcomes. A free account is enough.